The lack of a randomized trial comparing carfilzomib (K) versus elotuzumab (Elo) associated with lenalidomide and dexamethasone (Rd) prompted us to assess the relative usefulness of one triplet over the other. Five independent retrospective cohorts of 883 relapsed/refractory multiple myeloma (RRMM) patients, including 300 EloRd and 583 KRd cases, outside clinical trials, entered this non-randomized comparison. KRd cohort accounted for a higher incidence of younger patients, cases with ≥3 lines of therapy, already exposed to lenalidomide, International Staging System (ISS) stage III, and abnormal lactic dehydrogenase (LDH) level compared to EloRd cohort. Moreover, cytogenetic risk categories, detected in roughly one-third of cases, were equally distributed between the two therapy arms. The probability of CR+VGPR response was significantly higher in KRd (n=314, 53.9%) than in EloRd patients (n=111, 37.0%). Likewise, the cumulative incidence function of CR+VGPR, taking into account the competitive risk of death, was significantly higher in KRd arm patients than those in the EloRd arm (P=0.003). Moreover, KRd treatment significantly reduced the progression or death risk by 46% in an adjusted multivariate analysis (HR: 0.54, 95% CI 0.42-0.69, P<0.0001). Finally, in an adjusted illness progression/death model, the effect of KRd versus EloRd was of higher magnitude among those who achieved CR+VGPR (-39% hazard ratio reduction, P=0.02) than among those who achieved

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients / F. Morabito, E. Zamagni, C. Conticello, V. Pavone, S. Palmieri, S. Bringhen, M. Galli, S. Mangiacavalli, D. Derudas, E. Rossi, R. Ria, L. Catalano, P. Tacchetti, G. Mele, I.D. Vincelli, E.A. Martino, E. Vigna, C. Botta, A. Bruzzese, A. Mele, L. Pantani, S. Rocchi, B. Garibaldi, N. Cascavilla, S. Ballanti, G. Tripepi, F. Frigeri, A.P. Falcone, C. Cangialosi, G. Reddiconto, G. Farina, M. Barone, I. Rizzello, P. Musto, V. De Stefano, M. Musso, M.T. Petrucci, M. Offidani, A. Neri, N. Di Renzo, F. Di Raimondo, M. Boccadoro, M. Cavo, M. Gentile. - In: EUROPEAN JOURNAL OF HAEMATOLOGY. - ISSN 0902-4441. - (2021 Oct 30). [Epub ahead of print] [10.1111/ejh.13723]

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients

A. Neri;
2021-10-30

Abstract

The lack of a randomized trial comparing carfilzomib (K) versus elotuzumab (Elo) associated with lenalidomide and dexamethasone (Rd) prompted us to assess the relative usefulness of one triplet over the other. Five independent retrospective cohorts of 883 relapsed/refractory multiple myeloma (RRMM) patients, including 300 EloRd and 583 KRd cases, outside clinical trials, entered this non-randomized comparison. KRd cohort accounted for a higher incidence of younger patients, cases with ≥3 lines of therapy, already exposed to lenalidomide, International Staging System (ISS) stage III, and abnormal lactic dehydrogenase (LDH) level compared to EloRd cohort. Moreover, cytogenetic risk categories, detected in roughly one-third of cases, were equally distributed between the two therapy arms. The probability of CR+VGPR response was significantly higher in KRd (n=314, 53.9%) than in EloRd patients (n=111, 37.0%). Likewise, the cumulative incidence function of CR+VGPR, taking into account the competitive risk of death, was significantly higher in KRd arm patients than those in the EloRd arm (P=0.003). Moreover, KRd treatment significantly reduced the progression or death risk by 46% in an adjusted multivariate analysis (HR: 0.54, 95% CI 0.42-0.69, P<0.0001). Finally, in an adjusted illness progression/death model, the effect of KRd versus EloRd was of higher magnitude among those who achieved CR+VGPR (-39% hazard ratio reduction, P=0.02) than among those who achieved
elotuzumab; carfilzomib; dexamethasone; lenalidomide; multiple myeloma; salvage therapy
Settore MED/15 - Malattie del Sangue
30-ott-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
Morabito_Eur J Haematol_Oct 2021_accepted.pdf

embargo fino al 30/10/2022

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 232.58 kB
Formato Adobe PDF
232.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
ejh.13723.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 729.71 kB
Formato Adobe PDF
729.71 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/880266
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 0
social impact